Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current issues in anticoagulation.

Giancarlo Agnelli1

  • 1Stroke Unit and Cardiovascular Medicine, University of Perugia, Via Enrico dal Pozzo, IT-06123 Perugia, Italy. agnellig@unipg.it

Pathophysiology of Haemostasis and Thrombosis
|April 7, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.

The New England journal of medicine·2026
Same author

Left atrial enlargement and 1-year cerebrovascular events in subjects without atrial fibrillation: A prospective cohort study.

European journal of internal medicine·2026
Same author

Observational, Multicenter study on long-term Effectiveness and tolerability of aliROcumab (OMERO): an Italian real-life experience.

International journal of cardiology. Cardiovascular risk and prevention·2026
Same author

Optimising the Caravaggio score: developing a more universally applicable and comprehensive venous thromboembolism risk stratification tool. Author's reply.

European journal of internal medicine·2026
Same author

Right ventricular dysfunction on echocardiography to predict mortality in acute pulmonary embolism: an individual patient data meta-analysis.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Point-of-care ultrasonography (POCUS): a substantial help for the internists with some caveats.

European journal of internal medicine·2025
Same journal

Splenomegaly in primary antiphospholipid syndrome without accompanying portal hypertension or comorbidity.

Pathophysiology of haemostasis and thrombosis·2011
Same journal

The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease.

Pathophysiology of haemostasis and thrombosis·2011
Same journal

Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients.

Pathophysiology of haemostasis and thrombosis·2011
Same journal

The effect of chronic cadmium toxicity on blood pressure and plasma viscosity.

Pathophysiology of haemostasis and thrombosis·2011
Same journal

Serum and saliva sialic acid in periodontitis patients with and without cardiovascular disease.

Pathophysiology of haemostasis and thrombosis·2011
Same journal

Plasma tissue factor levels and salivary tissue factor activities of periodontitis patients with and without cardiovascular disease.

Pathophysiology of haemostasis and thrombosis·2011
See all related articles

New oral anticoagulants like ximelagatran offer improved treatment for thromboembolic disorders. This oral agent has a predictable profile, potentially increasing anticoagulation use and reducing management burdens.

Area of Science:

  • Pharmacology
  • Thrombosis Research
  • Internal Medicine

Background:

  • Current anticoagulation therapies (heparins, vitamin K antagonists) have limitations.
  • These limitations lead to underuse and inadequate treatment for many patients.
  • Heparins require injection and risk thrombocytopenia; VKAs have narrow therapeutic windows and interactions.

Purpose of the Study:

  • To introduce novel anticoagulants addressing limitations of existing therapies.
  • To highlight the potential of oral agents like ximelagatran.
  • To discuss improvements in anticoagulation management.

Main Methods:

  • Review of existing anticoagulation treatments and their drawbacks.
  • Introduction of new oral anticoagulants, including selective factor Xa inhibitors and direct thrombin inhibitors.

Related Experiment Videos

  • Focus on the properties of ximelagatran as a novel oral anticoagulant.

    • Main Results:

    • Ximelagatran, a direct thrombin inhibitor, is the first new oral anticoagulant in decades.
    • It offers an oral formulation with a predictable pharmacological profile.
    • No coagulation monitoring is required for ximelagatran therapy.

    Conclusions:

    • Ximelagatran has properties of an ideal anticoagulation agent.
    • Its oral formulation and predictable profile can increase anticoagulation use.
    • It has the potential to reduce the burden of long-term anticoagulation management.